Table 2.

Secondary analysis: adjusted odds of symptomatic SARS-CoV-2 infection, non-COVID-19 hospitalization, and non-COVID-19 pneumonia by time since first BNT162b2 dose.

	Adjusted odds ratio (95% CI)
Time relative to first vaccine dose	Symptomatic infection [N = 6,605 events]	Non-COVID-19 hospitalization [N = 6,441 events]	Non-COVID-19 pneumonia [N = 488 events]
Day 4	1 (Reference)	1 (Reference)	1 (Reference)
Days 10	1.23 (0.82–1.85)	0.93 (0.59–1.47)	0.24 (0.04–1.48)
Day 14	0.89 (0.63–1.25)	0.88 (0.61–1.27)	0.6 (0.16–2.25)
Day 21(Expected second dose)	0.62 (0.43–0.89)	0.86 (0.6–1.22)	0.23 (0.06–0.86)
Day 35(Expected full vaccination)	0.16 (0.11–0.23)	1 (0.72–1.38)	0.54 (0.18–1.59)
Day 85	0.26 (0.19–0.36)	0.78 (0.56–1.08)	0.43 (0.15–1.29)
Day 135	0.39 (0.29–0.53)	0.56 (0.4–0.78)	0.22 (0.07–0.68)
Day 185	0.45 (0.34–0.61)	0.46 (0.33–0.64)	0.22 (0.07–0.7)
Day 235	0.52 (0.39–0.7)	0.34 (0.24–0.48)	0.23 (0.07–0.72)
Day 285	0.5 (0.37–0.67)	0.32 (0.22–0.46)	0.22 (0.06–0.81)